Enanta Pharmaceuticals Inc. (ENTA)

100.52
1.97 1.92
NASDAQ : Health Technology
Prev Close 102.49
Open 102.65
Day Low/High 99.85 / 103.32
52 Wk Low/High 29.46 / 108.00
Volume 215.44K
Avg Volume 179.70K
Exchange NASDAQ
Shares Outstanding 19.27M
Market Cap 2.01B
EPS 0.90
P/E Ratio 39.40
Div & Yield N.A. (N.A)

Latest News

Enanta Pharmaceuticals Announces Data Presentations At The International Liver Congress™ 2018

Enanta Pharmaceuticals Announces Data Presentations At The International Liver Congress™ 2018

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that data from...

Enanta Pharmaceuticals To Present At The 2nd Annual H.C. Wainwright NASH Investor Conference

Enanta Pharmaceuticals To Present At The 2nd Annual H.C. Wainwright NASH Investor Conference

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Timothy D.

Enanta Pharmaceuticals To Present At Two Upcoming Investor Conferences

Enanta Pharmaceuticals To Present At Two Upcoming Investor Conferences

Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.

Enanta Pharmaceuticals Reports Financial Results For Its Fiscal First Quarter Ended December 31, 2017

Enanta Pharmaceuticals Reports Financial Results For Its Fiscal First Quarter Ended December 31, 2017

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for...

Enanta Pharmaceuticals To Host Conference Call On February 7 At 4:30 P.m. ET To Discuss Financial Results For Its Fiscal First Quarter Ended December 31, 2017

Enanta Pharmaceuticals To Host Conference Call On February 7 At 4:30 P.m. ET To Discuss Financial Results For Its Fiscal First Quarter Ended December 31, 2017

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to...

Enanta Pharmaceuticals To Provide Updates On Its Research And Development Programs And Business Outlook For 2018 During The 36th Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals To Provide Updates On Its Research And Development Programs And Business Outlook For 2018 During The 36th Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.

Enanta Pharmaceuticals To Present At The 36th Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals To Present At The 36th Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.

Enanta Pharmaceuticals Announces Data Presentations At The 2018 NASH-TAG Conference

Enanta Pharmaceuticals Announces Data Presentations At The 2018 NASH-TAG Conference

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a chemistry-driven biotechnology company dedicated to creating and developing small molecule drugs for viral infections and liver diseases, today announced that two presentations...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BMS, CNNE, ENTA, EXTN, GWW, HMNF, IQV, MCRN, RYAM, SVBI, TACO, WK Downgrades: ASFI, EHTH, HTM, PNNT, UBOH Initiations: PMTS, VRAY Read on to get TheStreet Quant Ratings' detailed report:

Enanta Pharmaceuticals Reaches Analyst Target Price

Enanta Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Enanta Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $53.00, changing hands for $53.98/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Enanta Announces That AbbVie's MAVIRET™ (glecaprevir/pibrentasvir) Is Now Available In Japan For The Treatment Of Chronic Hepatitis C Across All Major Genotypes (GT1-6)

Enanta Announces That AbbVie's MAVIRET™ (glecaprevir/pibrentasvir) Is Now Available In Japan For The Treatment Of Chronic Hepatitis C Across All Major Genotypes (GT1-6)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a chemistry-driven biotechnology company dedicated to creating and developing small molecule drugs for viral infections and liver diseases, today announced that AbbVie's...

Enanta Pharmaceuticals Reports Financial Results For Its Fourth Quarter And Year Ended September 30, 2017

Enanta Pharmaceuticals Reports Financial Results For Its Fourth Quarter And Year Ended September 30, 2017

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a chemistry-driven biotechnology company dedicated to creating and developing small molecule drugs for viral infections and liver diseases, today reported financial results for...

Enanta Pharmaceuticals To Host Conference Call On November 20 At 4:30 P.m. ET To Discuss Financial Results For Its Fiscal Fourth Quarter And Year Ended September 30, 2017

Enanta Pharmaceuticals To Host Conference Call On November 20 At 4:30 P.m. ET To Discuss Financial Results For Its Fiscal Fourth Quarter And Year Ended September 30, 2017

Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a chemistry-driven biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial...

Short Interest In Enanta Pharmaceuticals Moves 22.6% Lower

Short Interest In Enanta Pharmaceuticals Moves 22.6% Lower

The most recent short interest data has been released for the 10/31/2017 settlement date, which shows a 266,851 share decrease in total short interest for Enanta Pharmaceuticals Inc , to 913,160, a decrease of 22.61% since 10/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Enanta Pharmaceuticals Ranked As One Of North America's Fastest Growing Companies On Deloitte's 2017 Technology Fast 500™

Enanta Pharmaceuticals Ranked As One Of North America's Fastest Growing Companies On Deloitte's 2017 Technology Fast 500™

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a chemistry-driven biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced its inclusion on Deloitte's Technology...

Enanta Pharmaceuticals Announces Positive Phase 1 A/b Clinical Results For Its Lead FXR Agonist, EDP-305

Enanta Pharmaceuticals Announces Positive Phase 1 A/b Clinical Results For Its Lead FXR Agonist, EDP-305

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a chemistry-driven biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced positive results from its Phase 1...

Enanta Pharmaceuticals To Present New Preclinical Data On EDP-305, An FXR Agonist For NASH And PBC, At The Liver Meeting® 2017

Enanta Pharmaceuticals To Present New Preclinical Data On EDP-305, An FXR Agonist For NASH And PBC, At The Liver Meeting® 2017

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a chemistry-driven biotechnology company dedicated to creating and developing small molecule drugs for viral infections and liver diseases, today announced new data presentations...

Enanta Announces Data To Be Presented On AbbVie's MAVYRET™ (glecaprevir/pibrentasvir) At The Liver Meeting® 2017

Enanta Announces Data To Be Presented On AbbVie's MAVYRET™ (glecaprevir/pibrentasvir) At The Liver Meeting® 2017

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a chemistry-driven biotechnology company dedicated to creating and developing small molecule drugs for viral infections and liver diseases, today announced, that AbbVie will...

Enanta Pharmaceuticals Announces New Data Presentations On EDP-305, An FXR Agonist For NASH And PBC, At The Liver Meeting® 2017

Enanta Pharmaceuticals Announces New Data Presentations On EDP-305, An FXR Agonist For NASH And PBC, At The Liver Meeting® 2017

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new data presentations...

Enanta Announces That AbbVie's MAVIRET™ (glecaprevir/pibrentasvir) Received Approval In Japan For The Treatment Of All Major Genotypes (GT1-6) Of Chronic Hepatitis C

Enanta Announces That AbbVie's MAVIRET™ (glecaprevir/pibrentasvir) Received Approval In Japan For The Treatment Of All Major Genotypes (GT1-6) Of Chronic Hepatitis C

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the Japanese...

Enanta Pharmaceuticals Announces The Appointment Of Kristine Peterson To Its Board Of Directors

Enanta Pharmaceuticals Announces The Appointment Of Kristine Peterson To Its Board Of Directors

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced the appointment of Kristine Peterson to its Board of Directors.

Enanta Pharmaceuticals To Present At Three Upcoming Investor Conferences

Enanta Pharmaceuticals To Present At Three Upcoming Investor Conferences

Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.

Enanta Pharmaceuticals Reports Financial Results For Its Fiscal Third Quarter Ended June 30, 2017

Enanta Pharmaceuticals Reports Financial Results For Its Fiscal Third Quarter Ended June 30, 2017

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for...

Enanta Announces U.S. FDA Approval Of AbbVie's MAVYRET™ (glecaprevir/pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6) In As Little As 8 Weeks

Enanta Announces U.S. FDA Approval Of AbbVie's MAVYRET™ (glecaprevir/pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6) In As Little As 8 Weeks

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the U.

Enanta Announces European Commission Grants AbbVie Marketing Authorization For MAVIRET® (glecaprevir/pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

Enanta Announces European Commission Grants AbbVie Marketing Authorization For MAVIRET® (glecaprevir/pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the European...

Enanta Pharmaceuticals To Host Conference Call On August 7 At 4:30 P.m. ET To Discuss Financial Results For Its Fiscal Third Quarter Ended June 30, 2017

Enanta Pharmaceuticals To Host Conference Call On August 7 At 4:30 P.m. ET To Discuss Financial Results For Its Fiscal Third Quarter Ended June 30, 2017

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to...

Interesting ENTA Put And Call Options For August 18th

Interesting ENTA Put And Call Options For August 18th

Investors in Enanta Pharmaceuticals Inc saw new options become available this week, for the August 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ENTA options chain for the new August 18th contracts and identified one put and one call contract of particular interest.

Enanta Announces New Data On EDP-938, A Novel Non-Fusion Inhibitor Of Respiratory Syncytial Virus (RSV), At The XIX International Symposium On Respiratory Viral Infections

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new data on EDP-938,...

TheStreet Quant Rating: B (Buy)